Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis Pharmaceuticals has received a $1 million milestone payment from Merck & Co. triggered by the initiation of trials for a compound discovered by the two companies.
Subscribe to our email newsletter
Isis said the unnamed compound takes advantage of its expertise in nucleic acid therapeutics. The company's research is focused exclusively on the therapeutic target, RNA and focuses on disease areas such as ocular, viral and neurodegenerative diseases, and cancer.
“We're pleased to see Merck advancing this molecule in clinical trials. The compound was created out of our productive collaboration,” commented Isis' senior vice president of Research, Frank Bennett.